Cost-effectiveness of personalized omalizumab dosing for chronic spontaneous urticaria.

Denman, Sarah; Smith, Helin; Arumugakani, Gururaj; Mistry, Anoop; Savic, Sinisa

Denman, Sarah; Smith, Helin; Arumugakani, Gururaj; Mistry, Anoop; Savic, Sinisa.

Afiliación

Denman S; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, Yorkshire, UK.
Smith H; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, Yorkshire, UK.
Arumugakani G; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, Yorkshire, UK.
Mistry A; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, Yorkshire, UK.
Savic S; Department of Clinical Immunology and Allergy, St James's University Hospital, Leeds, Yorkshire, UK.

Clin Exp Dermatol ; 47(11): 2002-2005, 2022 Nov.

Article en En | MEDLINE | ID: mdl-35775857

Asunto(s)

Antialérgicos; Urticaria Crónica; Urticaria; Humanos; Omalizumab; Antialérgicos/efectos adversos; Urticaria/tratamiento farmacológico; Urticaria/inducido químicamente; Análisis Costo-Beneficio; Enfermedad Crónica; Resultado del Tratamiento

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Urticaria / Antialérgicos / Urticaria Crónica Tipo de estudio: Guideline / Health_economic_evaluation Límite: Humans Idioma: En Revista: Clin Exp Dermatol Año: 2022 Tipo del documento: Article País de afiliación: Reino Unido

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google